- Apostolos Tsapas, assistant professor1,
- Thomas Karagiannis, research fellow1,
- Paschalis Paschos, research fellow1,
- Konstantinos Paletas, professor1,
- David R Matthews, professor in diabetic medicine2
- 1Aristotle University Thessaloniki, 54642, Thessaloniki, Greece
- 2Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
- atsapas{at}auth.gr
We appreciate Scheffel and Schaan’s response to our systematic review.1 2 Our meta-analysis provides evidence that dipeptidyl peptidase-4 (DPP-4) inhibitors are indeed inferior to metformin and GLP-1 agonists on the primary endpoint of change in glycated haemoglobin (HbA1c). However, we do not agree with their interpretation of …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
PDF
Social bookmarking